Management of psychocutaneous disorders: A practical approach for dermatologists.
management
psychocutaneous
psychodermatology
treatment
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
30
06
2020
accepted:
02
07
2020
pubmed:
6
7
2020
medline:
29
4
2021
entrez:
5
7
2020
Statut:
ppublish
Résumé
Psychodermatology is a growing specialty which is gaining momentum in different parts of the world. It focuses on the connection between skin and psyche. Psychocutaneous conditions are characterized by those disorders where stress is the key element in exacerbating skin conditions or flare ups of dermatoses like psoriasis and atopic dermatitis. There is a direct relationship of stress with the course, and prognosis of the skin disease. In some situations, there is no skin condition but the lesions are self-inflicted and such disorders are always associated with underlying psychopathology or psychological conflicts. Sometimes emotional problems are more prominent as a result of having skin disease, and the psychological consequences may be more severe than the physical symptoms. Management of these conditions require a combination of psychpharmacology, psychotherapy, and liaison clinics of psychiatry and dermatology. This review focuses on the common management approach which can be adopted by dermatologists in treating patients with psychodermatological disorders, improving doctor-patient relationship and therapeutic bond.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13969Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Jafferany M, Ferreira BR, Patel A. The Essentials of Psychodermatology. Cham, Switzerland: Springer International Publishing; 2020:29-34.
Tohid H, Shenefelt PD, Burney WA, Aqeel N. Psychodermatology: an association of primary psychiatric disorders with skin. Rev Colomb Psiquiatr. 2019;48(1):50-57.
Reichenberg JS, Kroumpouzos G, Magid M. Approach to a psychodermatology patient. G Ital Dermatol Venereol. 2018;153(4):494-496.
Jafferany M, Franca K. Psychodermatology: basics concepts. Acta Derm Venereol. 2016;96(217):35-37.
Korabel H, Dudek D, Jaworek A, Wojas-Pelc A. Psychodermatology: psychological and psychiatrical aspects of dermatology. Przegl Lek. 2008;65(5):244-248.
Tran A, Desir AK, Okafor LC, Jafferany M, Copes LE. Psychodermatology in clinical practice: an examination of physician attitudes, beliefs and interventions towards psychocutaneous disease. Dermatol Ther. 2020;e13612. https://doi.org/10.1111/dth.13612. [Epub ahead of print].
Picari A, Abeni D. Stressful life events and skin diseases: disentangling evidence from myth. Psychother Psychosom. 2001;70:118-136.
Dhabhar FS. Psychological stress and immunoprotection vs. immunopathology in the skin. Clin Dermatol. 2013;31:18-30.
Jafferany M, Salimi S, Mkhoyan R, Kalashnikova N, Sadoughifar R, Jorgaqi E. Psychological aspects of aesthetic and cosmetic surgery: clinical and therapeutic implications. Dermatol Ther. 2020;e13727.
Hafi B, Uvais NA, Jafferany M, Afra TP, Muhammed RT. Palliative psychodermatology care during COVID-19 pandemic. Dermatol Ther. 2020;e13732.
Jafferany M, Patel A. Understanding psychocutaneous disease: psychosocial & psychoneuroimmunologic perspectives. Int J Dermatol. 2019;59:8-15. https://doi.org/10.1111/ijd.14629.
Bowe WP, Logan AC. Acne vulgaris, probiotics and the gut-brain-skin axis-back to the future? Gut Pathog. 2011;3(1):1.
Soderholm JD, Perdue MH. Stress and gastrointestinal tract. II. Stress and intestinal barrier function. Am J Physiol Gastrointest Liver Physiol. 2001;280(1):G7-G13.
Sawant NS, Vanjari NA, Khopkar U, Adulkar S. A study of depression and quality of life in patients of lichen planus. Sci World J. 2015;2015:817481.
Kwan Z, Bong YB, Tan LL, et al. Determinants of quality of life and psychological status in adults with psoriasis. Arch Dermatol Res. 2018;310(5):443-451.
Martínez-Ortega JM, Nogueras P, Muñoz-Negro JE, Gutiérrez-Rojas L, González-Domenech P, Gurpegui M. Quality of life, anxiety and depressive symptoms in patients with psoriasis: a case-control study. J Psychosom Res. 2019;124:109780.
Kota RS, Vora RV, Varma JR, Kota SK, Patel TM, Ganjiwale J. Study on assessment of quality of life and depression in patients of Vitiligo. Indian Dermatol Online J. 2019;10(2):153-157.
Bonotis K, Pantelis K, Karaoulanis S, et al. Investigation of factors associated with health-related quality of life and psychological distress in vitiligo. J Dtsch Dermatol Ges. 2016;14(1):45-48.
Simons RE, Zevy DL, Jafferany M. Psychodermatology of vitiligo: psychological impact and consequences. Dermatol Ther. 2020;33(3):e13418.
Koszorú K, Borza J, Gulácsi L, Sárdy M. Quality of life in patients with atopic dermatitis. Cutis. 2019;104(3):174-177.
Yumeen S, Abrouk ME, Maderal AD. Acne, the new trend? A discussion of the emerging social movement to embrace acne vulgaris. Int J Dermatol. 2020. https://doi.org/10.1111/ijd.14969 [Epub ahead of print].
Ferreira BR, Cardoso JC, Reis JP, Figueiredo A. Acne. In: França K, Lotti T, eds. Advances in Integrative Dermatology. Oxford, UK: Wiley Blackwell; 2019:33-56.
Elsaie LT, Elshahid AR, Hasan HM, Soultan FAZM, Jafferany M, Elsaie ML. Cross sectional quality of life assessment in patients with androgenetic alopecia. Dermatol Ther. 2020;e13799 [Epub ahead of print].
Patel A, Jafferany M. Multidisciplinary and holistic models of care for patients with dermatologic disease and psychosocial comorbidity: a systematic review. JAMA Dermatol. 2020. https://doi.org/10.1001/jamadermatol.2020.0394 [Epub ahead of print].
Ferreira BR, Pio-Abreu JL, Reis JP, Figueiredo A. First psychodermatology clinic in a Portuguese Department of Dermatology. J Eur Acad Dermatol Venereol. 2019;33(3):e119-e120.
Elpern DJ. Medically unexplained dermatologic symptoms still a problem. J Eur Acad Dermatol Venereol. 2018;32(12):e449.
Finlay AY, Khan GK. Dermatology life quality index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210-216.
Singh RK, Finlay AY. DLQI use in skin disease guidelines and registries worldwide. J Eur Acad Dermatol Venereol. 2020. https://doi.org/10.1111/jdv.16701 (published online ahead of print).
Vanheule S, Desmet M, Groenvynck H, Rosseel Y, Fontaine J. The factor structure of the Beck depression inventory-II: an evaluation. Assessment. 2008;15(2):177-187.
Beck AT, Steer RA, Brown GK. Manual for the Beck Depression Inventory-II. San Antonio, TX: Psychological Corporation; 1996.
Lovibond SH, Lovibond PF. Manual for the Depression Anxiety Stress Scales. 2nd ed. Sydney, Australia: Psychology Foundation of Australia; 1995.
Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361-370.
Choi GS, Nam YH, Park CS, et al. Anxiety, depression, and stress in Korean patients with chronic urticaria. Korean J Intern Med. 2020. https://doi.org/10.3904/kjim.2019.320 (published online ahead of print).
White D, Leach C, Sims R, Atkinson M, Cottrell D. Validation of the hospital anxiety and depression scale for use with adolescents. Br J Psychiatry. 1999;175:452-454.
Schneider G, Grebe A, Bruland P, Heuft G, Ständer S. Criteria suggestive of psychological components of itch and Soma-toform itch: study of a large sample of patients with chronic pruritus. Acta Derm Venereol. 2020;100(6):adv00075-adv00077.
Dalgard FJ, Sjöström K, Fhager J, Svensson Å, Wallin E, Hauksson I. Subjective and objective characteristics of patients seen at a psychodermatology unit: one-year experience in Malmö, Sweden. Acta Derm Venereol. 2020;100(8):adv00126.
Abramowitz JS, Deacon BJ, Olatunji BO, et al. Assessment of obsessive-compulsive symptom dimensions: development and evaluation of the dimensional obsessive-compulsive scale. Psychol Assess. 2010;22(1):180-198.
Ekhtiari H, Rezapour T, Aupperle RL, Paulus MP. Neuroscience-informed psychoeducation for addiction medicine: a neurocognitive perspective. Prog Brain Res. 2017;235:239-264.
Ferreira BR, Pio-Abreu JL, Reis JP, Figueiredo A. Medically unexplained dermatologic symptoms and psychodermatology. J Eur Acad Dermatol Venereol. 2018;32(12):e447-e448.
Affleck A, Chouliara Z, Kielty S. Cognitive behavioral therapy for acne and other chronic skin disorders. Int J Dermatol. 2014;53(4):e246-e247.
Williams C, Garland A. A cognitive-behavioral therapy assessment model for use in everyday clinical practice. Adv Psychiatr Treat. 2002;16(2):114-122.
Ansari F, Pourjafar H, Tabrizi A, Homayouni A. The effects of probiotics and prebiotics on mental disorders: a review on depression, anxiety, Alzheimer, and autism spectrum disorders. Curr Pharm Biotechnol. 2020;21(7):555-565.
Shah B, Levenson JL. Use of psychotropic drugs in the dermatology patient: when to start and stop? Clin Dermatol. 2018;36(6):748-755.
Dong N, Nezgovorova V, Hong K, Hollander E. Pharmacotherapy in body dysmorphic disorder: relapse prevention and novel treatments. Expert Opin Pharmacother. 2019;20(10):1211-1219.
Kotara S, Magid M, Burrows M. Psychopharmacology in psychodermatology. In: Bewley A, Taylor RE, Reichenberg JS, Magid M, eds. Practical Psychodermatology. UK: Wiley Blackwell; 2014:21-32.
Tomas-Aragones L, Consoli SM, Consoli SG, et al. Self-inflicted lesions in dermatology: a management and therapeutic approach-a position paper from the European Society for Dermatology and Psychiatry. Acta Derm Venereol. 2017;97(29):159-172.
Jafferany M, Kobusiewicz A, Ferreira BR, Garan S, Havryliuk O. Factitious disorders in children: clinical and therapeutic consideration. Dermatol Venereol. 2019;2(84):8-14.
Reid WH, Kirwin S. Risk and risk management in psychodermatology. In: Bewley A, Taylor RE, Reichenberg JS, Magid M, eds. Practical Psychodermatology. UK: Wiley Blackwell; 2014:50-59.
Osman OT, Souid AK, Al-Mugaddam F, Eapen BR, Jafferany M. Attentiveness of dermatologists in the Middle East to psychocutaneous medicine. Prim Care Companion CNS Disord. 2017;19(2). https://doi.org/10.4088/PCC.16m02080.